CTA
NVAX icon

Carillon Tower Advisers’s Novavax NVAX Stock Holding History

Carillon Tower Advisers’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$10M Sell
90,011
-4,371
-5% -$465K 0.06% 334
2020
Q3 		$10.2M Buy
+94,382
New +$11.5M 0.14% 250

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Carillon Tower Advisers's NVAX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Novavax (NVAX) stake by 4.6% in Q4 2020, selling an estimated $465K and leaving 90,011 shares worth $10M. The position accounts for 0.06% of the portfolio, ranked #334.

Carillon Tower Advisers first reported a position in NVAX in Q3 2020 and has held it in 2 quarters since. The position peaked at $10.2M in Q3 2020. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

  • Carillon Tower Advisers held 90,011 shares of Novavax worth $10M as of Q4 2020.
  • Carillon Tower Advisers sold 4,371 Novavax shares in Q4 2020, an estimated $465K.
  • Novavax made up 0.06% of Carillon Tower Advisers's portfolio in Q4 2020, its #334 holding.
  • Carillon Tower Advisers first reported a position in Novavax in Q3 2020 and has held it in 2 quarters since.
  • Carillon Tower Advisers's Novavax position peaked at $10.2M in Q3 2020.
  • 347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.